Securian Asset Management Inc. Sells 100 Shares of Insulet Co. (NASDAQ:PODD)

Securian Asset Management Inc. lessened its position in Insulet Co. (NASDAQ:PODD) by 2.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,749 shares of the medical instruments supplier’s stock after selling 100 shares during the period. Securian Asset Management Inc.’s holdings in Insulet were worth $979,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of PODD. Venturi Wealth Management LLC increased its stake in Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares in the last quarter. SBI Securities Co. Ltd. bought a new stake in shares of Insulet during the fourth quarter worth $36,000. SRS Capital Advisors Inc. increased its position in shares of Insulet by 43.1% during the fourth quarter. SRS Capital Advisors Inc. now owns 186 shares of the medical instruments supplier’s stock worth $49,000 after acquiring an additional 56 shares in the last quarter. TD Private Client Wealth LLC increased its position in shares of Insulet by 32.6% during the third quarter. TD Private Client Wealth LLC now owns 228 shares of the medical instruments supplier’s stock worth $53,000 after acquiring an additional 56 shares in the last quarter. Finally, Friedenthal Financial bought a new stake in shares of Insulet during the fourth quarter worth $57,000.

Insider Buying and Selling

In related news, EVP Eric Benjamin sold 12,394 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $280.00, for a total transaction of $3,470,320.00. Following the transaction, the executive vice president now directly owns 11,383 shares of the company’s stock, valued at approximately $3,187,240. This trade represents a 52.13 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.47% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on PODD. TD Cowen increased their price objective on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a research report on Friday, January 3rd. JPMorgan Chase & Co. increased their price objective on shares of Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research report on Thursday, December 12th. Citigroup increased their target price on shares of Insulet from $310.00 to $355.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Royal Bank of Canada started coverage on shares of Insulet in a report on Thursday, March 6th. They set an “outperform” rating and a $340.00 target price for the company. Finally, Canaccord Genuity Group increased their target price on shares of Insulet from $304.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, February 21st. Four equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $292.06.

Insulet Price Performance

Shares of PODD opened at $255.44 on Friday. The firm has a market capitalization of $17.94 billion, a PE ratio of 44.12, a PEG ratio of 3.62 and a beta of 1.29. The company’s 50-day moving average is $272.54 and its 200-day moving average is $254.96. Insulet Co. has a fifty-two week low of $160.19 and a fifty-two week high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share for the quarter, beating the consensus estimate of $1.00 by $0.15. The company had revenue of $597.50 million for the quarter, compared to analyst estimates of $582.02 million. Insulet had a net margin of 20.19% and a return on equity of 24.46%. Equities analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.